Q1 EPS Forecast for Fate Therapeutics Boosted by Analyst
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Equities research analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for Fate Therapeutics in a research note issued to investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.42) per share for the […]
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Equities research analysts at Wedbush raised their Q1 2025 earnings per share (EPS) estimates for Fate Therapeutics in a research note issued to investors on Wednesday, March 5th. Wedbush analyst D. Nierengarten now expects that the biopharmaceutical company will post earnings of ($0.42) per share for the […]
